Actively Recruiting
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Led by University of California, Irvine · Updated on 2026-02-05
82
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
CONDITIONS
Official Title
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Advanced or metastatic non-small cell lung cancer (NSCLC) patients
- At least 18 years old on the day of signing informed consent
- Signed the informed consent form
- Eligible to receive FDA approved or non-approved PD1 inhibitors (e.g., pembrolizumab, nivolumab), PDL1 inhibitors (e.g., atezolizumab, durvalumab), alone or with chemotherapy, or tyrosine kinase inhibitors
- Registration occurs upon submission of stool and saliva samples, with the latest submission date as registration date
You will not qualify if you...
- Clinically unstable patients as determined by the principal investigator or treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California, United States, 92868
Actively Recruiting
Research Team
C
Chao Family Comprehensive Cancer Center University of California, Irvine
CONTACT
U
University of California Irvine Medical
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here